This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Highly Active Anti-Retroviral Therapies (HAART) that include HIV-1 protease inhibitors (PI) have greatly reduced HIV related mortality rates. However, many of these patients develop lipodystrophy, characterized by redistribution of body fat and insulin resistance. Hypertriglyceridemia and impaired glucose tolerance has been noted in 5- to 70% of patients treated with PI containing regimens. Low leptin levels have also been reported in some of these patients with selective loss of subcutaneous adipose tissue. We have recently demonstrated the efficacy of leptin replacement therapy in non HIV-infected patients with other genetic and acquired lipodystrophies. The purpose of this study is to investigate the safety and efficacy of leptin therapy in patients with HAART associated lipodystrophy.
Showing the most recent 10 out of 693 publications
